Table 2.
Univariable and multivariable analyses of overall survival and progression-free survival by antibiotic class.
| Variables * | Overall Survival | Progression-Free Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable Analysis |
Multivariable Analysis |
Univariable Analysis |
Multivariable Analysis |
|||||
| HR (95% CI) |
p-Value | HR (95% CI) |
p-Value | HR (95% CI) |
p-Value | HR (95% CI) |
p-Value | |
| Anti-pseudomonal beta-lactamase inhibitor (piperacillin/tazobactam) |
3.31 (1.77–6.18) |
<0.001 | 3.31 (1.77–6.18) |
<0.001 | 1.43 (0.91–2.23) |
0.119 | 3.40 (1.82–6.34) |
<0.001 |
| Beta-lactamase inhibitors | 0.28 (0.04–2.11) |
0.220 | 0.47 (0.19–1.16) |
0.100 | - | - | ||
| Cephalosporins, 1st generation |
1.17 (0.46–2.98) |
0.749 | 0.83 (0.44–1.54) |
0.549 | ||||
| Cephalosporins, 2nd generation |
0.50 (0.12–2.09) |
0.345 | 0.78 (0.39–1.56) |
0.489 | ||||
| Cephalosporins, 3rd generation |
1.67 (0.85–3.28) |
0.140 | - | - | 0.84 (0.52–1.37) |
0.492 | ||
| Fluoroquinolones | 2.88 (1.54–5.37) |
<0.001 | - | - | 1.24 (0.80–1.92) |
0.338 | ||
| Glycopeptides | 3.22 (1.26–8.25) |
0.015 | - | - | 1.40 (0.65–3.03) |
0.391 | ||
| Sulfamethoxazole/ trimethoprim |
2.24 (0.99–5.06) |
0.053 | - | - | 1.08 (0.58–2.03) |
0.802 | ||
* Anti-tuberculosis medications, carbapenem (meropenem), fourth-generation cephalosporin (cefepime), imidazole (metronidazole), macrolides and tetracycline (doxycycline) were not included in this univariable and multivariable analysis due to small sample sizes (<5).